A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2018 Planned End Date changed from 1 Dec 2020 to 1 Mar 2022.
- 29 Sep 2016 Status changed from not yet recruiting to recruiting.